Remove Biobanking Remove Drugs Remove Genomics
article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 129
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanks are used for the coordination of high-yield patient sample collection. Partnerships and Establishing Research Cohorts.

article thumbnail

Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk

Pharmaceutical Technology

Using data from the UK Biobank database, genomic sequencing data for 360,000 individuals were obtained and the findings were confirmed in animal models that demonstrated a higher expression of the INHBE gene in obese monkeys when compared to more lean monkeys.

Gene 130
article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

article thumbnail

Digitalising drug discovery

pharmaphorum

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? , According to an article by Stephens, Zachary D.,

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.